Welcome!

Progress in the Quest for an AIDS Vaccine

Posted: December 20th, 2012 | Author: | Filed under: Travel Vaccines Updates | Tags: , , , , | Comments Off on Progress in the Quest for an AIDS Vaccine

Good news out of Canada in the search for an HIV vaccine: Scientists announced a vaccine candidate showed no adverse effects and significantly boosted immunity in human trials.

Researchers from the Schulich School of Medicine & Dentistry at Western University in Ontario are working on a vaccine dubbed SAV001-H, the only HIV vaccine being developed in Canada. The vaccine, approved by the FDA for clinical trials last year, uses a killed whole HIV-1 virus to spark an immune response. The same strategy was used to develop influenza, polio, rabies and hepatitis A vaccines.

In the Phase I study, HIV-positive men and women aged 18 to 50 were split into two groups, with 18 people receiving the vaccine and 6 getting a placebo.

“There were no adverse effects,” Dr. Chil-Yong Kang, professor of virology at the Schulich School of Medicine & Dentistry, told the Toronto Star. “And after the vaccination, the level of (HIV-1) antibodies increased significantly. That means our vaccine is working to stimulate the immune responses.”

In one individual, researchers saw a thirty-twofold increase in the level of HIV-1 antibodies. Another showed a tenfold increase.

Now, researchers will move on to Phase II, a study slated to begin next year. This yearlong study will test the vaccine on 600 HIV-negative volunteers at high risk for infection so researchers can gauge immune response.

Enhanced by Zemanta

Finally! A Vaccine for Allergy Relief

Posted: September 18th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , , , , | Comments Off on Finally! A Vaccine for Allergy Relief

Allergy Therapeutics will court a partner to market its Pollinex Quattro Grass vaccine now that the FDA lifted a clinical hold on the grass pollen allergy shot.

The company can move forward with a Phase III efficacy study, which will take place in an environmental exposure chamber, according to a release. The vaccine–commercialized in some European countries–comes as a four-shot series, requiring the injections over the course of a year.

Vaccines research at the NVGH

Vaccines research at the NVGH (Photo credit: Novartis AG)

The FDA froze the vaccine in 2007, after a volunteer experienced numbness and weakness during a trial. Allergy Therapeutics’ stock tumbled 22% at the time, according to FierceBiotech. But the U.K.-based company’s shares jumped almost 30% after the FDA lifted the hold.

“This product has the potential to greatly benefit allergy sufferers in the U.S.in the absence of registered products by being the first subcutaneous immunotherapy vaccine to reach the U.S.market,” said CEO Manuel Llobet. “Additionally, lifting the hold will allow for discussions with potential partners with whom we will finalize the clinical development and start the commercialization of Pollinex Quattro in a market estimated to be around $2 billion.”